Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
GRI similar filings
- 26 May 23 Financial Statements and Exhibits
- 27 Apr 23 Other Events
- 27 Apr 23 Regulation FD Disclosure
- 21 Apr 23 Investment proceeds expected to fund planned operations of the combined company into mid-2024
- 20 Apr 23 Vallon Pharmaceuticals Announces Stockholder Approval of Merger with GRI Bio, Inc. and Reverse Stock Split
- 12 Apr 23 Vallon Pharmaceuticals Adjourns Special Meeting of Stockholders Until
- 7 Apr 23 Other Events
Filing view
External links
Exhibit 16.1
April 21, 2023
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Ladies and Gentleman:
We have read Item 4.01 of Form 8-K dated April 21, 2023 of GRI Bio, Inc. (formerly known as Vallon Pharmaceuticals, Inc.) and are in agreement with the statements contained therein as it regards our firm. We have no basis to agree or disagree with other statements of the registrant contained in Item 4.01.
Sincerely,
/s/ EisnerAmper LLP | |||||
EisnerAmper LLP |